LSE · AZN.L
AstraZeneca PLC
£136.40+£5.88 (+4.51%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 13.3% below the high.
Loading market information…
OTC · PLLWF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Polarean Imaging plc’s quoted price sits in the upper half of its reported 52-week range, 1.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Polarean Imaging plc’s next earnings report is currently expected on Jun 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Polarean Imaging plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Polarean Imaging plc operates as a specialized entity within the medical imaging sector, focusing on integrated drug-device solutions. The company extends its services across international markets, including the United States, Canada, Germany, and the United Kingdom. At its core, Polarean is engaged in the creation and market introduction of advanced gas polarizer systems and associated ancillary instruments. A significant aspect of their innovation lies in developing specialized equipment that enhances conventional magnetic resonance imaging (MRI) machines, enabling them to perform advanced functional pulmonary imaging. The company distinguishes itself by specializing in the application of hyperpolarized xenon gas (129Xe) as a unique imaging agent. This technology allows for the detailed visualization of regional ventilation and gas exchange within the lungs, particularly in the smallest airways, the interface between the lung tissue and the bloodstream, and the pulmonary vasculature, thereby offering a novel diagnostic method. Furthermore, Polarean Imaging plc is actively involved in the design and manufacturing of the specific MRI radiofrequency coils that are indispensable for imaging 129Xe within an MRI system. Established in 2016, the company's base of operations is located in Durham, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 |
|---|
| May 18, 2022 |
| -$0.04+14.42% vs estimate |
| $563.55K-70.34% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£136.40+£5.88 (+4.51%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 13.3% below the high.
$5.80-$0.10 (-1.69%)
Regional Health Properties, Inc.’s quoted price sits in the lower half of its reported 52-week range, 13.43% below the high.
$2.84$0.00 (0.0%)
Talis Biomedical Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Reliq Health Technologies Inc.: Healthcare · Medical - Healthcare Information Services.
$0.00+$0.00 (+33.33%)
Lifeline Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.64% below the high.
$0.00$0.00 (0.0%)
AXIM Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.66% below the high.
$0.01$0.00 (0.0%)
Nu-Med Plus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.0% below the high.
$0.00$0.00 (0.0%)
Resilient Healthcare Corp’s quoted price sits in the lower half of its reported 52-week range, 92.98% below the high.
